Holen Sie sich die Stockscreener-App
0.9526
17.43%
0.1436
Schlusskurs vom Vortag:
$0.809
Offen:
$0.851
24-Stunden-Volumen:
8.22M
Relative Volume:
1.88
Marktkapitalisierung:
$20.10M
Einnahmen:
$1.44M
Nettoeinkommen (Verlust:
$-21.34M
KGV:
-0.7124
EPS:
-1.3371
Netto-Cashflow:
$-17.38M
1W Leistung:
+96.44%
1M Leistung:
+77.30%
6M Leistung:
+20.62%
1J Leistung:
-42.07%
1-Tages-Spanne:
$0.8425
$1.10
1-Wochen-Bereich:
$0.4901
$1.17
52-Wochen-Spanne:
$0.475
$1.9198
Longeveron Inc Stock (LGVN) Company Profile
Firmenname
Longeveron Inc
Sektor
Branche
Telefon
305-302-7158
Adresse
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.942 | 17.26M | 1.44M | -21.34M | -17.38M | -1.3371 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.99 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
701.04 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.13 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.61 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
Longeveron Inc Aktie (LGVN) Neueste Nachrichten
Longeveron Announces $30 Million Private Placement Financing - TipRanks
Best Biotech Stocks To Keep An Eye On – March 10th - Defense World
Longeveron closes $15 million financing, extends runway to 4Q26 - Investing.com Australia
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026 - Bitget
Longeveron closes $15 million financing, extends runway to 4Q26 By Investing.com - Investing.com South Africa
Longeveron Announces Closing of Private Placement of up to $30 Million - Bitget
Biotech Longeveron secures $15M, cash runway past 2026 HLHS trial readout - Stock Titan
A $30 Million Reason to Buy Penny Stock Longeveron Today - Barchart.com
Longeveron secures $15M financing with potential for additional $15M tied to trial milestones - MSN
Longeveron secures $15M financing, eyes $15M more on trial results - Investing.com South Africa
Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal - Benzinga
Longeveron Inc. (LGVN) Stock: Surges 60% as Company Secures $30M Private Placement Funding - parameter.io
LGVN Longeveron (NASDAQ) +97.64% intraday 10 Mar 2026: earnings 12 Mar to watch - Meyka
Longeveron prices 6.01M shares at 52c in private placement - TipRanks
Longeveron jumps 70.7% as investors react to up to $30M private placement financing - Quiver Quantitative
Biotech Stock Longeveron Inc. (NASDAQ: LGVN) Makes Nasdaq Top Gainer List on News - Investorideas.com
Longeveron Announces Private Placement of up to $30 Million - Yahoo Finance
Block Trades: Can Longeveron Inc outperform in the next rally2026 Technicals & Consistent Growth Equity Picks - baoquankhu1.vn
Longeveron Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Merger Talk: How cyclical is Longeveron Incs revenue streamLayoff News & Technical Pattern Based Buy Signals - baoquankhu1.vn
Aug Sentiment: Is Longeveron Inc exposed to currency risks2025 Market Outlook & Weekly Breakout Watchlists - baoquankhu1.vn
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Cantech Letter
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga
Longeveron Inc. (LGVN) asks shareholders to OK 1:5–1:20 reverse split to meet Nasdaq - Stock Titan
LGVN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LGVN: Trial Results Encouraging - Research Tree
LGVN Should I Buy - Intellectia AI
Longeveron Reports Positive Phase 2b Clinical Trial Results - Intellectia AI
Longeveron Inc. Reports Positive Trial Results for Age-Related Therapy - Intellectia AI
Longeveron Shares Fall After Releasing Phase 2b Data From Age-Related Frailty Study - marketscreener.com
Longeveron publishes phase 2b stem cell trial results in journal - Investing.com
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty In Study - Stocktwits
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - Bitget
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - The Manila Times
Stem cell therapy helps frailty patients walk farther in Longeveron trial - Stock Titan
Longeveron publishes phase 2b stem cell trial results in journal By Investing.com - Investing.com India
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Aug Movers: Can Longeveron Inc outperform in the next rallyEarnings Summary Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Q1 Earnings Forecast for Longeveron Issued By Zacks Research - Defense World
Will Longeveron Inc. stock hit new highs in YEARMarket Performance Recap & Intraday High Probability Alerts - mfd.ru
Longeveron (LGVN) Projected to Post Quarterly Earnings on Friday - Defense World
Trade Recap: Does Longeveron Inc offer margin of safetyJuly 2025 Sentiment & Free High Return Stock Watch Alerts - baoquankhu1.vn
LGVN SEC FilingsLongeveron Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Is Longeveron Inc. a strong candidate for buy and holdQuarterly Risk Review & Consistent Profit Focused Trading Strategies - mfd.ru
LGVN: New CEO and Fresh Cost Reductions - Research Tree
Longeveron Appoints Stephen Willard as CEO - citybiz
Surprises Report: Is Longeveron Inc stock a value trapJuly 2025 Breakouts & Risk Managed Investment Strategies - baoquankhu1.vn
Longeveron Appoints New CEO to Lead Pivotal Clinical Trials - National Today
Longeveron Appoints New CEO Amid Cost-Cutting Initiatives - The Globe and Mail
Is Longeveron Inc. on track to beat earningsJuly 2025 Weekly Recap & Weekly Watchlist of Top Performers - mfd.ru
Finanzdaten der Longeveron Inc-Aktie (LGVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Longeveron Inc-Aktie (LGVN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):